Akero Therapeutics | EFX for MASH | Metabolic Disease | Home
Akero Therapeutics is a clinical-stage company developing transformational therapies for people with metabolic dysfunction-associated steatohepatitis (MASH). Akero Therapeutics Announces …
Akero's stock doubles as midphase MASH trial hits the mark
4 days ago · Akero Therapeutics has hit a home run, reporting statistically significant results in two key 96-week metabolic dysfunction-associated steatohepatitis (MASH) analyses to send …
Akero Therapeutics Stock Doubles on Liver Disease Drug Trial …
4 days ago · Akero Therapeutics shares traded near their all-time high as the drugmaker reported positive results in a study of its treatment for liver disease. The drug, known as EFX, helped …
Akero Therapeutics, Inc. (AKRO) - Yahoo Finance
Find the latest Akero Therapeutics, Inc. (AKRO) stock quote, history, news and other vital information to help you with your stock trading and investing.
Akero Therapeutics Announces Proposed Public Offering of …
SOUTH SAN FRANCISCO, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for …
Akero Therapeutics | Efruxifermin (EFX) for MASH | Company
Akero is a clinical-stage company developing transformational medicines for people with serious metablic diseases such as MASH. Akero Therapeutics Announces Week 96 Results from …
Akero Therapeutics | Efruxifermin for MASH | Pipeline
Akero Therapeutics is a clinical-stage company developing transformational therapies for people with metabolic dysfunction-associated steatohepatitis (MASH). Akero Therapeutics Announces …
Akero Therapeutics Announces Proposed Public Offering of …
4 days ago · Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, …
Akero Therapeutics Reports Statistically Significant Histological ...
Mar 4, 2024 · Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, …
In Akero Therapeutics’ Phase 2b HARMONY Study, Both the …
Sep 13, 2022 · In July of 2021, Akero initiated the SYMMETRY study, a Phase 2b trial in biopsy-confirmed NASH patients with compensated cirrhosis (F4), Child-Pugh class A. Based on …